Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to on
To evaluate the hypothesis that breakthrough acromegaly symptom exacerbation frequency would be reduced after switching biochemically controlled patients from depot somatostatin receptor ligand (SRL) injections to once-daily oral paltusotine. Biochemical disease control (insulin-
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.